Insider Selling: Kiniksa Pharmaceuticals International (NASDAQ:KNSA) CEO Sells $1,217,601.44 in Stock

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) CEO Sanj Patel sold 22,544 shares of Kiniksa Pharmaceuticals International stock in a transaction that occurred on Wednesday, April 29th. The shares were sold at an average price of $54.01, for a total transaction of $1,217,601.44. Following the transaction, the chief executive officer owned 431,904 shares of the company’s stock, valued at $23,327,135.04. The trade was a 4.96% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Kiniksa Pharmaceuticals International Stock Up 2.8%

Shares of NASDAQ KNSA opened at $55.27 on Friday. Kiniksa Pharmaceuticals International, plc has a twelve month low of $24.85 and a twelve month high of $55.28. The firm has a market cap of $4.23 billion, a P/E ratio of 61.41 and a beta of 0.17. The company has a 50 day moving average of $46.40 and a 200 day moving average of $43.16.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last announced its quarterly earnings data on Tuesday, April 28th. The company reported $0.27 earnings per share for the quarter, topping analysts’ consensus estimates of $0.18 by $0.09. Kiniksa Pharmaceuticals International had a net margin of 9.69% and a return on equity of 13.26%. The company had revenue of $214.27 million during the quarter, compared to analyst estimates of $206.11 million. During the same period in the previous year, the business earned $0.11 EPS. The firm’s revenue for the quarter was up 55.5% on a year-over-year basis. As a group, equities analysts expect that Kiniksa Pharmaceuticals International, plc will post 1.22 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Kiniksa Pharmaceuticals International

A number of large investors have recently added to or reduced their stakes in the stock. Mark Sheptoff Financial Planning LLC grew its position in Kiniksa Pharmaceuticals International by 1.6% in the 4th quarter. Mark Sheptoff Financial Planning LLC now owns 16,350 shares of the company’s stock worth $674,000 after purchasing an additional 250 shares during the period. Mariner LLC grew its position in Kiniksa Pharmaceuticals International by 2.0% in the 4th quarter. Mariner LLC now owns 13,519 shares of the company’s stock worth $558,000 after purchasing an additional 266 shares during the period. Virtus Investment Advisers LLC grew its position in shares of Kiniksa Pharmaceuticals International by 2.5% during the 4th quarter. Virtus Investment Advisers LLC now owns 16,432 shares of the company’s stock valued at $678,000 after acquiring an additional 406 shares during the period. Mercer Global Advisors Inc. ADV grew its position in shares of Kiniksa Pharmaceuticals International by 7.1% during the 4th quarter. Mercer Global Advisors Inc. ADV now owns 7,684 shares of the company’s stock valued at $317,000 after acquiring an additional 508 shares during the period. Finally, EverSource Wealth Advisors LLC grew its position in shares of Kiniksa Pharmaceuticals International by 140.4% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 911 shares of the company’s stock valued at $25,000 after acquiring an additional 532 shares during the period. Institutional investors own 53.95% of the company’s stock.

Key Headlines Impacting Kiniksa Pharmaceuticals International

Here are the key news stories impacting Kiniksa Pharmaceuticals International this week:

• Positive Sentiment: Q1 beat and upgraded guidance — Kiniksa reported $0.27 EPS vs. $0.18 consensus and revenue of $214.3M (≈+55% YoY); management raised FY‑2026 revenue guidance, improving near‑term revenue visibility. Q1 Results & Guidance
• Positive Sentiment: Analyst upgrades/target raises — multiple brokers lifted targets (examples: Jefferies to $71, Canaccord to $64, Citi to $60, Wedbush to $59), which supports buying interest and helped push the stock higher. Analyst Target Raises
• Positive Sentiment: Product and pipeline momentum — ARCALYST reported strong Q1 net product revenue and management raised expectations; KPL‑387 Phase‑2 readout (recurrent pericarditis) is expected 2H‑2026 with a planned Phase‑3 start by year‑end, offering future catalysts. Product & Pipeline
• Neutral Sentiment: Earnings materials available — Q1 slide deck and call transcript posted for investors who want to verify channel dynamics, margin assumptions and guidance drivers. Earnings Presentation
• Negative Sentiment: Large insider selling — CEO Sanj K. Patel executed significant sales (including 483,654 shares on Apr. 28 and additional tranches Apr. 29–30) under a pre‑arranged 10b5‑1 plan; director Barry Quart also sold ~13k shares. Heavy insider selling can create short‑term negative sentiment despite being pre‑planned. CEO SEC Filing
• Negative Sentiment: Director sale detail — Director Barry D. Quart sold 13,099 shares (~$50.10 avg) under a 10b5‑1 plan, reducing his stake materially; additional SEC filing here. Director SEC Filing

Analyst Ratings Changes

A number of equities analysts recently weighed in on KNSA shares. Citigroup boosted their price objective on shares of Kiniksa Pharmaceuticals International from $50.00 to $60.00 and gave the stock a “buy” rating in a report on Wednesday. Weiss Ratings restated a “hold (c)” rating on shares of Kiniksa Pharmaceuticals International in a report on Tuesday, April 21st. Wedbush boosted their price objective on shares of Kiniksa Pharmaceuticals International from $58.00 to $59.00 and gave the stock an “outperform” rating in a report on Wednesday. Wells Fargo & Company boosted their price objective on shares of Kiniksa Pharmaceuticals International from $53.00 to $57.00 and gave the stock an “overweight” rating in a report on Wednesday. Finally, Zacks Research lowered shares of Kiniksa Pharmaceuticals International from a “hold” rating to a “strong sell” rating in a report on Friday, April 17th. Seven analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $60.86.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.